Glucagon in β‐Blocker and Calcium Channel Blocker Overdoses: A Systematic Review

References

• Davis S. N., Granner D. K. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. Goodman and Gilman's The Pharmacological Basis of Therapeutics, J. G. Hardman, L. E. Limbird. McGraw‐Hill, New York 1996; 1487–1517
   Google Scholar
• Farah A., Tuttle R. Studies on the pharmacology of glucagon. J Pharm Exp Ther 1960; 129: 49–55
   PubMed Web of Science ®Google Scholar
• Glick G., Parmsley W. W., Wechsler A. S., Sonnenblick E. H. Glucagon: its enhancement of cardiac performance in the cat and dog and persistence of its action despite beta‐receptor blockade with propranonol. Circ Research 1968; 22: 789–799
   PubMed Web of Science ®Google Scholar
• Lucchesi B. R. Cardiac actions of glucagon. Circ Research 1968; 22: 777–787
   PubMed Web of Science ®Google Scholar
• Kosinski E. J., Stern N., Malindzak G. S.J., Boone E. Glucagon and propranolol (inderal) toxicity. New Engl J Med 1971; 285: 1325
   PubMed Web of Science ®Google Scholar
• Crump B. J., Holt D. W., Vale J. A. Lack of response to intravenous calcium in severe verapamil poisoning. Lancet 1982; 2: 939–940
   PubMed Web of Science ®Google Scholar
• Howland M. A. Glugagon. Goldfrank's Toxicologic Emergencies, L. R. Goldfrank, N. E. Flomenbaum, N. A. Lewin, R. S. Weisman, M. A. Howland, R. S. Hoffman. Appleton and Lange, Stamford 1998; 827
   Google Scholar
• Ellenhorn M. J. Ellenhorn's Medical Toxicology. Williams and Wilkins, Baltimore 1997
   Google Scholar
• Benowitz N. L. Propranolol (inderal) and beta‐blocker toxicity. Clinical Management of Poisoning and Drug Overdose, L. M. Haddad, J. F. Winschester. WB Saunders, Philadelphia 1983; 850
   Google Scholar
• Dreisbach R. H., Robertson W. O. Handbook of Poisoning: Prevention, Diagnosis and Treatment. Appleton and Lange, Norwalk 1987
   Google Scholar
• Goldfrank L. R., Flomenbaum N. E., Lewin N. A., Weisman R. S. Toxicologic Emergencies. A Comprehensive Handbook in Problem Solving. Appleton‐Century‐Crofts, New York 1982
   Google Scholar
• Goldfrank L. R., Flomenbaum N. E., Lewin N. A., Weisman R. S., Howland M. A., Kulberg A. G. Goldfrank's Toxicologic Emergencies. Appleton‐Century‐Crofts, Norwalk 1986
   Google Scholar
• Howland M. A. Glucagon. Goldfrank's Toxicologic Emergencies, L. R. Goldfrank, N. E. Flomenbaum, N. A. Lewin, R. S. Weinstein, M. A. Howland, A. G. Kulberg. Appleton‐Century‐Crofts, Norwalk 1986; 285–286
   Google Scholar
• Howland M. A. Glucagon. Goldfrank's Toxicologic Emergencies, L. R. Goldfrank, N. E. Flomenbaum, N. A. Lewin, R. S. Weisman, M. A. Howland. Appleton and Lange, Norwalk 1990; 378–379
   Google Scholar
• Haddad L. M., Shannon M. W., Winschester J. F. Clinical Management of Poisoning and Drug Overdose. WB Saunders, Philadelphia 1998
   Google Scholar
• Ford M. D., Delaney K. A., Ling L. J., Erickson T. Clinical Toxicology. WB Saunders, Philadelphia 2001
   Google Scholar
• Bryson P. D. Comprehensive Review in Toxicology for Emergency Physicians. Taylor and Francis, Washington 1996
   Google Scholar
• Goldfrank L. R., Flomenbaum N. E., Lewin N. A., Weisman R. S., Howland M. A., Hoffman R. S. Goldfrank's Toxicologic Emergencies. Appleton and Lange, Stamford 1998
   Google Scholar
• Goldfrank L. R., Flomenbaum N. E., Lewin N. A., Howland M. A., Hoffman R. S., Nelson L. Goldfrank's Toxicologic Emergencies. McGraw‐Hill, New York 2002
   Google Scholar
• Juni P., Altman D. G., Egger M. Assessing the quality of randomised controlled trials. Systematic Reviews in Health Care—Meta‐Analysis in Context, M. Egger, G. D. Smith, D. G. Altman. BMJ book, London 2001; 87–108
   Google Scholar
• Love J. N., Leasure J. A., Mundt D. J., Janz T. G. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Tox Clin Toxicol 1992; 30: 399–412
   PubMed Web of Science ®Google Scholar
• Toet A. E., Wemer J., Vleeming W., de Biesebeek J. D., Meulenbelt J., de Wildt D. J. Experimental study of the detrimental effect of dopamine/glucagon combination in d,l‐propranolol intoxication. Hum Exp Toxicol 1996; 15: 411–421
   PubMed Web of Science ®Google Scholar
• Love J. N., Sachdeva D. K., Bessman E. S., Curtis L. A., Howell J. M. A potential role for glucagon in the treatment of drug‐induced symptomatic bradycardia. Chest 1998; 114: 323–326
   PubMed Web of Science ®Google Scholar
• Stone C. K., May W. A., Carroll R. Treatment of verapamil overdose with glucagon in dogs. Ann Emerg Med 1995; 25: 369–374
   PubMed Web of Science ®Google Scholar
• Kerns W. I., Schroeder D., Williams C., Tomaszewski C., Raymond R. Insulin improves survival in a canine model of acute beta‐blocker toxicity. Ann Emerg Med 1997; 29: 748–757
   PubMed Web of Science ®Google Scholar
• Love J. N., Hanfling D., Howell J. M. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. Ann Emerg Med 1996; 28: 1–6
   PubMed Web of Science ®Google Scholar
• Sato S., Tsuji M. H., Okubo N., Naito H. Milrinone versus glucagon: comparative hemodynamic effects in canine propranolol poisoning. J Tox Clin Toxicol 1994; 32: 277–289
   PubMed Web of Science ®Google Scholar
• Sato S., Tsuji M. H., Okubo N., Nishimoto C., Naito H. Combined use of glucagon and milrinone may not be preferable for severe propranolol poisoning in the canine model. J Tox Clin Toxicol 1995; 33: 337–342
   PubMed Web of Science ®Google Scholar
• Chernow B., Reed L., Geelhoed G. W., Anderson M., Teich S., Meyerhoff J., Beardsley D., Lake C. R., Holaday J. W. Glucagon: endocrine effects and calcium involment in cardiovascular actions in dogs. Circ Shock 1986; 19: 393–407
   PubMedGoogle Scholar
• Benvenistry A. I., Spotnitz H. M., Rose E. A., Malm J. R., Hoffman B. F. Antagonism of chronic canine beta‐adrenergic blockade with dopamine‐isoproterenol, dobutamine, and glucagon. Surg Forum 1979; 30: 187–188
   PubMedGoogle Scholar
• Peterson A., Lucchesi B., Kirsh M. The effects of glucagon in animals on chronic propranolol therapy. Ann Thorac Surg 1978; 25: 340–345
   PubMed Web of Science ®Google Scholar
• Kosinski E. J., Malindzak G. S.J. Glucagon and isoproterenol in reversing propranolol toxicity. Arch Inter Med 1973; 132: 840–843
   PubMed Web of Science ®Google Scholar
• Madan B. R., Gupta R. S., Jain B. K. Pulmonary vascular and cardiac effects of glucagon before and after adrenergic beta‐receptor blockade. Indian J Physiol Pharmacol 1971; 15: 173–177
   PubMedGoogle Scholar
• Brooks H., Banas J. S.J., Dalen J. E., Dexter L. Cardiovascular and contractile responses to nondepressant beta‐adrenergic blockade. Amer J Physiol 1971; 221: 138–143
   PubMed Web of Science ®Google Scholar
• Zaritsky A. L., Horowitz M., Chernow B. Glucagon antagonism of calcium channel blocker‐induced myocardial depression. Crit Care Med 1988; 16: 246–251
   PubMed Web of Science ®Google Scholar
• Whitsitt L. S., Lucchesi B. R. Effects of beta‐receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circ Research 1968; 23: 585–595
   PubMed Web of Science ®Google Scholar
• Levey G. S., Epstein S. Activation of adenyl cyclase by glucagon in cat and human heart. Circ Research 1969; 24: 151–156
   PubMed Web of Science ®Google Scholar
• Jolly S. R., Kipnis J. N., Lucchesi B. R. Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol. Pharmacology 1987; 35: 249–255
   PubMed Web of Science ®Google Scholar
• Chernow B., Zaloga G. P., Willey S. C., Clapper M., Holaday J. W. Glucagon's chronotropic action is calcium dependent. J Pharm Exp Ther 1987; 241: 833–837
   PubMed Web of Science ®Google Scholar
• Love J. N., Leasure J. A., Mundt D. J. A comparison of combined amrinone and glucagon therapy to glucagon alone for cardiovascular depression associated with propranolol toxicity in a canine model. Amer J Emerg Med 1993; 11: 360–363
   PubMed Web of Science ®Google Scholar
• Tuncok Y., Apaydin S., Gidener S., Guven H., Oto O., Ates M., Gure A. The effects of amrinone and glucagon on verapamil‐induced myocardial depression in a rat isolated heart model. Gen Pharmacol 1997; 28: 773–776
   PubMedGoogle Scholar
• Tuncok Y., Apaydin S., Kalkan S., Ates M., Guven H. The effects of amrinone and glucagon on verapamil‐induced cardiovasular toxicity in anesthetized rats. Int J Exp Path 1996; 77: 207–212
   PubMed Web of Science ®Google Scholar
• Stone C. K., Thomas S. H., Koury S. I., Low R. B. Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose. Acad Emerg Med 1996; 3: 120–125
   PubMed Web of Science ®Google Scholar
• Kline J. A., Tomaszewski C. A., Schroeder J. D., Raymond R. M. Insuline is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharm Exp Ther 1993; 267: 744–750
   PubMed Web of Science ®Google Scholar
• Sabatier J., Pouyet T., Shelvey G., Cavero I. Antagonistic effects of epinephrine, glucagon and methylatropine but not calcium chloride against atrio‐ventricular conduction disturbances produced by high doses of diltiazem, in conscious dogs. Fundam Clin Pharmacol 1991; 5: 93–106
   PubMed Web of Science ®Google Scholar
• Schoffstall J. M., Spivey W. H., Gambone L. M., Shaw R. P., Sit S. P. Effects of calcium channel blocker overdose‐induced toxicity in the conscious dog. Ann Emerg Med 1991; 20: 1104–1108
   PubMed Web of Science ®Google Scholar
• Sauvadet A., Rohn T., Pecker F., Pavoine C. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Research 1996; 78: 102–109
   PubMed Web of Science ®Google Scholar
• Zaloga G. P., Malcolm D., Holaday J. W., Chernow B. Glucagon reverses the hypotension and bradycardia of verapamil overdose in rats. Crit Care Med 1985; 13: 273
   Web of Science ®Google Scholar
• Chernow B., Reed L., Geelhoed G. W., Myerhoff J., Lake C. R., Beardsley D., Holaday J. Verapamil antagonizes glucagon's chronotropic effect. Circ Shock 1984; 13: 96–97
   Google Scholar
• Farah A. E. Glucagon and the circulation. Pharmacol Reviews 1983; 35: 181–217
   PubMed Web of Science ®Google Scholar
• Hall‐Boyer K., Zaloga G. P., Chernow B. Glucagon: hormone or therapeutic agent?. Crit Care Med 1984; 12: 584–589
   PubMed Web of Science ®Google Scholar
• Parmsley W. W., Glick G., Sonnenblick E. H. Cardiovascular effects of glucagon in man. New Engl J Med 1968; 279: 12–17
   PubMed Web of Science ®Google Scholar
• Martin T. G. Advanced life support in the poisoned patient (Tox ACLS). Clinical Toxicology, M. D. Ford, K. A. Delaney, L. J. Ling, T. Erickson. WB Saunders, Philadelphia 2001; 12–20
   Google Scholar
• Albertson T. E., Dawson A., de LaTorre F., Hoffman R. S., Hollander J. E., Jaeger A., Kerns W., II, Martin T. G., Ross M. P. Tox‐ACLS: toxicologic‐oriented advanced cardiac life support. Ann Emerg Med 2001; 37: S78–S90
   PubMed Web of Science ®Google Scholar